Thursday, 15 October 2026European Markets

KOMPLETT Stock Bullish Momentum With A 9.88% Rise Today

Loading stream...

(VIANEWS) - The Market ended the session with KOMPLETT (KOMPL.OL) jumping 9.88% to kr11.34 on Wednesday, after three sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI fell 0.14% to kr1,289.59, following the last session's downward trend on what was a somewhat down trend trading session today.

KOMPLETT's last close was kr10.32, 48.3% under its 52-week high of kr19.96.

About KOMPLETT

Komplett ASA operates as an online retailer of electronics and IT products in Norway, Sweden, and Denmark. The company operates through three segments: Business to Consumer (B2C), Business to Business (B2B), and Distribution. It offers consumer electronics and business solutions, including computer components, gaming, PCs, household electronics, and other computer-related products, as well as brown and white goods, and cloud-based IT solutions and services. It operates webshops under the Komplett brand; and retail stores under the Webhallen brand. The company's B2B operations include sales to companies and public entities/institutions under the Komplett Bedrift and Komplett Företag. It also distributes products to resellers and other entities under the Itegra brand. The company was formerly known as Norkom ASA and changed its name to Komplett ASA in December 2002. Komplett ASA was founded in 1991 and is headquartered in Sandefjord, Norway.

Earnings Per Share

As for profitability, KOMPLETT has a trailing twelve months EPS of kr-1.51.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.19%.

Sales Growth

KOMPLETT's sales growth for the current quarter is 3.7%.

More news about KOMPLETT (KOMPL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com